Patents Assigned to Curative Technologies, Inc.
  • Patent number: 5599558
    Abstract: A method of making a platelet releasate product is disclosed involving performing an assay on a platelet releasate sample for a component of the releasate and forming platelet releasate product by comparing the assay results to a predetermined range of amounts of the component to be contained in the product. A method of treatment of tissue is disclosed involving the topical application of such product.
    Type: Grant
    Filed: October 25, 1994
    Date of Patent: February 4, 1997
    Assignee: Curative Technologies, Inc.
    Inventors: Richard H. Gordinier, Ronald G. Duff, Dawn D. Newmann
  • Patent number: 5470831
    Abstract: The present invention relates to peptides and peptide derivatives related to platelet factor 4 which exhibit angiogenic activity, to pharmaceutical compositions comprising said peptides, and to methods for promoting angiogenesis utilizing said peptides. It is based, in part, on the discovery that an octapeptide derived from platelet factor 4 and seven structurally related peptides (depicted in FIG. 1) are capable of inducing an angiogenic response in vivo as measured by neovascularization in rabbit corneal implant assay and by measurement of capillary endothelial cell chemoattraction. The angiogenic peptides of the invention may be particularly useful in promoting wound healing, including incisional healing, bone repair, burn healing, and post-infarction repair in myocardial injury, and in facilitating the assimilation of grafted tissues, particularly in persons suffering from vascular insufficiency, such as diabetic patients.
    Type: Grant
    Filed: March 24, 1993
    Date of Patent: November 28, 1995
    Assignee: Curative Technologies, Inc.
    Inventors: Russell B. Whitman, Robert Wohl, Ronald G. Duff
  • Patent number: 5178883
    Abstract: Platelet enriched plasma is produced from blood. The platelets are activated by thrombine which causes therelease of platelet-derived growth and angiogenesis factors. A carrier such as a microcrystalline collagen is added to produce a wound-treating salve. The composition is applied directly to wounds and initiates healing in nonhealing wounds as well as accelerating normal wound-healing by increasing vascularization, stimulating fibroblast mitrosis and migration, and increasing collagen synthesis by fibroblasts. The composition is also applied to tissue to facilitate the growth of hair.
    Type: Grant
    Filed: May 18, 1990
    Date of Patent: January 12, 1993
    Assignees: Regents of the University of Minnesota, Curative Technologies, Inc.
    Inventor: David R. Knighton
  • Patent number: 5165938
    Type: Grant
    Filed: May 18, 1990
    Date of Patent: November 24, 1992
    Assignees: Regents of the University of Minnesota, Curative Technologies, Inc.
    Inventor: David R. Knighton